Log in automatically

Log in | New user?


DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy
                   
tmcnet.com     May 22, 2008            

EWING, NJ, May 22 / MARKET WIRE/ -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism...


Full Coverage:

                   

DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy

redorbit.com     May 22, 2008          

Posted on: Thursday, 22 May 2008, 09:01 CDT DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain...

analysis/comments

                   

DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy

pharmiweb.co.uk     May 22, 2008          

EWING, NJ -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism agents, announced today...

analysis/comments

                   

DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy (Marketwire)

yahoo.com     May 22, 2008          

Thursday May 22, 8:00 am ET DOR Enters Into Letter of Intent With IDIS for Named Patient Access of orBec(R) in Europe EWING, NJ--(MARKET WIRE)--May 22, 2008 -- News ) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of...

analysis/comments

                   

DOR BioPharma, Inc.: DOR BioPharma Provides Update on orBec(R) European Regulatory and...

marketwire.com     May 22, 2008          

EWING, NJ (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism agents,...

analysis/comments

Q1 financial results reported for DOR BioPharma Inc

m2.com     May 19, 2008          

Published in M2 EquityBites on Monday, 19 May 2008 at 15:53 GMT DOR BioPharma Inc (OTCBB:DORB.OB), a biopharmaceutical company, reported on 16 May its financial results for the first quarter ended 31 March 2008. The company's revenues for the first quarter were USD0.7m, an increase when compared...

analysis/comments